Cadrenal Therapeutics, Common Stock Today
| CVKD Stock | 14.01 0.49 3.38% |
Performance12 of 100
| Odds Of DistressLess than 46
|
Cadrenal Therapeutics, is trading at 14.01 as of the 21st of November 2024, a 3.38 percent decrease since the beginning of the trading day. The stock's lowest day price was 14.0. Cadrenal Therapeutics, has 46 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. Equity ratings for Cadrenal Therapeutics, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of January 2023 | Category Healthcare | Classification Health Care |
Cadrenal Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 1.66 M outstanding shares of which 39.48 K shares are currently shorted by private and institutional investors with about 0.65 trading days to cover. More on Cadrenal Therapeutics, Common
Moving together with Cadrenal Stock
Moving against Cadrenal Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cadrenal Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman CEO | Quang Pham | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
| Cadrenal Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cadrenal Therapeutics,'s financial leverage. It provides some insight into what part of Cadrenal Therapeutics,'s total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||
Cadrenal Therapeutics, Common (CVKD) is traded on NASDAQ Exchange in USA. It is located in 822 A1A North, Ponte Vedra, FL, United States, 32082 and employs 4 people. Cadrenal Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.05 M. Cadrenal Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.66 M outstanding shares of which 39.48 K shares are currently shorted by private and institutional investors with about 0.65 trading days to cover.
Cadrenal Therapeutics, generates negative cash flow from operations
Check Cadrenal Therapeutics, Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cadrenal Therapeutics, is USD24.05 Million. Cadrenal Therapeutics, Common retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cadrenal Ownership Details
Cadrenal Therapeutics, Historical Income Statement
Cadrenal Stock Against Markets
Cadrenal Therapeutics, Corporate Executives
Elected by the shareholders, the Cadrenal Therapeutics,'s board of directors comprises two types of representatives: Cadrenal Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cadrenal. The board's role is to monitor Cadrenal Therapeutics,'s management team and ensure that shareholders' interests are well served. Cadrenal Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cadrenal Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
When determining whether Cadrenal Therapeutics, is a strong investment it is important to analyze Cadrenal Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cadrenal Therapeutics,'s future performance. For an informed investment choice regarding Cadrenal Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.